Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
V419 Lot-to-Lot Consistency Study in Healthy Infants
NCT01340937Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- May 2011
- Primary completion
- Dec 2012
- Modality
- Split/Subunit Vaccines
01
Overview
A Phase 3 trial of DTaP-IPV-Hep B-PRP-T vaccine in diphtheria, Tetanus, pertussis, poliomyelitis, Haemophilus influenzae type b infection (Hib), sponsored by Merck & Co.. Started May 2011; status: completed.
02
Drugs
DTaP-IPV-Hep B-PRP-T vaccine
03
Conditions
diphtheriaTetanuspertussispoliomyelitisHaemophilus influenzae type b infection (Hib)
Beyond the preview
Go deeper on NCT01340937.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01340937.